Toshiba seeks new multivendor partner
After less than two years of partnership, multimodality vendor Toshiba America Medical Systems of Tustin, CA, and independent service organization COHR of Chatsworth, CA, have agreed to discontinue their asset management and multivendor service contract,
After less than two years of partnership, multimodality vendor Toshiba America Medical Systems of Tustin, CA, and independent service organization COHR of Chatsworth, CA, have agreed to discontinue their asset management and multivendor service contract, according to Toshiba executives. The companies established their partnership in April 1997, with COHR agreeing to provide multivendor and asset management services for Toshiba (SCAN 4/30/97).
But in October, the two firms decided not to continue their partnership, according to Brian Turnbull, vice president of Toshiba's Technology Services business unit. Toshiba is continuing its relationship with COHR's Purchase Connection division, a unit that offers group purchasing services to members and gives Toshiba another outlet for equipment sales. As for multivendor and asset management services, Toshiba is now seeking other options, Turnbull said.
In the two years since it signed the agreement with Toshiba, COHR has had its share of turbulence. The company may find more stable ground soon: COHR signed a definitive merger agreement with Three Cities Research of New York in December (SCAN 1/13/99).
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
